Search Result

Results for "

VIP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenylate Cyclase (3) Apoptosis (8) Calcium Channel (2) CDK (6) CMV (1) DNA/RNA Synthesis (6) Drug Isomer (4) EGFR (2) Elastase (1) ERK (2) GCGR (4) Histone Methyltransferase (2) HIV (1) Integrin (1) IPK Superfamily (2) Liposome (4) PACAP Receptor (17) PD-1/PD-L1 (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) SARS-CoV (2) Small Interfering RNA (siRNA) (4) WDR5 (2)
By Research Areas:	Cancer (11) Cardiovascular Disease (6) Endocrinology (1) Infection (4) Inflammation/Immunology (14) Metabolic Disease (9) Neurological Disease (15)
Oligonucleotides:	Pegylated Lipids (4) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-P0012

Aviptadil 2 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-103019

Enitociclib 2 Publications Verification (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Inflammation/Immunology Cancer
Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC₅₀=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK Apoptosis DNA/RNA Synthesis	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-P0221C

PACAP (1-38) free acid	PACAP Receptor	Metabolic Disease
PACAP (1-38) free acid is a desamido-PACAP (1-38), human, ovine, rat (HY-P0221). PACAP (1-38) free acid can activate the human PAC1 receptor. PACAP (1-38) free acid induces cyclic AMP (cAMP) generation in both NS-1 neuroendocrine cells and non-neuroendocrine HEK293 cells .

HY-P0220A

PACAP (6-38), human, ovine, rat TFA 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat TFA is a potent PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P1023

VIP(6-28)(human, rat, porcine, bovine) 1 Publications Verification	GCGR	Metabolic Disease
VIP(6-28)(human, rat, porcine, bovine) is an effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP.

HY-P5005

VIPhyb	CMV PD-1/PD-L1	Infection Inflammation/Immunology Cancer
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .

HY-P0220

PACAP (6-38), human, ovine, rat 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat is a potent PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-103019B

(-)-Enitociclib 2 Publications Verification (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Cancer
(-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-P0012A

Aviptadil acetate 2 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting *VIP-VPAC2* signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting *VIP-VPAC2* signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P4195A

*[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate*	IPK Superfamily	Metabolic Disease
[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is the acetate of [K15,R16,L27]VIP(1-7)/GRF(8-27) (HY-P4195). [K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate), a *VIP₁* selective agonist, exhibits IC₅₀ values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP₁, rat VIP₁, rat VIP₂ receptors, respectively . VIP: VASOACTIVE Intestinal Polypeptide

HY-P1159A

*[D-p-Cl-Phe6,Leu17]-VIP* TFA** 1 Publications Verification	PACAP Receptor	Neurological Disease Inflammation/Immunology
[D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of *vasoactive intestinal peptide (VIP) receptor, with the IC₅₀* of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors .

HY-P10948A

*CS-VIP* 8 hydrochloride**	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 hydrochloride is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 hydrochloride induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 hydrochloride is promising for research of hematological diseases such as leukemia .

HY-P4776

*Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP* (1-7)-GRF (8-27)**	PACAP Receptor	Metabolic Disease
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), a vasoactive intestinal peptide (VIP), is a VIP₁ antagonist .

HY-P1159

[D-p-Cl-Phe6,Leu17]-VIP	PACAP Receptor	Neurological Disease Inflammation/Immunology
[D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of *vasoactive intestinal peptide (VIP) receptor, with the IC₅₀* of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors .

HY-P4127A

M65 TFA	PACAP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .

HY-P1015

VIP(Guinea pig) Vasoactive Intestinal Peptide, guinea pig	PACAP Receptor	Neurological Disease Metabolic Disease
VIP Guinea pig (Vasoactive intestinal peptide), a trophic and mitogenic factor, stimulates growth in whole cultured embryos. VIP Guinea pig functions as a simple gastrointestinal hormone and suggest a possible neurotransmitter function .

HY-P10948

*CS-VIP* 8**	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 is promising for research of hematological diseases such as leukemia .

HY-P4015

VIP (1-12), human, porcine, rat, ovine	HIV	Neurological Disease Metabolic Disease
VIP (1-12), human, porcine, rat, ovine is a vasoactive intestinal peptide (VIP) fragment. VIP (1-12), human, porcine, rat, ovine is a ligand for the CD4 (T4)/human immunodeficiency virus receptor .

HY-P10768A

Ro 25-1553 TFA	PACAP Receptor	Inflammation/Immunology
Ro 25-1553 TFA is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 TFA exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .

HY-P3117

PACAP (6-27) (human, ovine, rat) Pituitary adenylate cyclase-activating peptide (6-27)	Adenylate Cyclase	Neurological Disease
PACAP (6-27) (human, ovine, rat) is a PACAP receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases .

HY-P1767

*Prepro VIP* (81-122), human**	PACAP Receptor	Cardiovascular Disease
Prepro VIP (81-122), human is a prepro-vasoactive intestinal polypeptide (VIP) derived peptide, corresponding to residues 81-122. Peptide histidine valine 42 (PHV-42) has been designated to correspond exactly to Prepro VIP (81-122), which reduces both the force and frequency of spontaneous contractions of isolated rat uterus .

HY-P1158

[Ala2,8,9,11,19,22,24,25,27,28]-VIP	Adenylate Cyclase	Neurological Disease
[Ala2,8,9,11,19,22,24,25,27,28]-VIP is an analog vasoactive intestinal polypeptide (VIP) with high affinity and selectivity for human VIP/pituitary adenylate cyclase-activating polypeptide 1 (hVPAC1). VIP is a widespread neurotransmitter .

HY-P4195

*[K15,R16,L27]VIP(1-7)/GRF(8-27)*	IPK Superfamily	Metabolic Disease
[K15,R16,L27]VIP(1-7)/GRF(8-27), a *VIP₁* selective agonist, exhibits IC₅₀ values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP₁, rat VIP₁, rat VIP₂ receptors, respectively . VIP: VASOACTIVE Intestinal Polypeptide

HY-P10768

Ro 25-1553	PACAP Receptor	Inflammation/Immunology
Ro 25-1553 is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .

HY-P3050

Helospectin II	GCGR	Cardiovascular Disease
Helospectin II is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin II has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin II is originally isolated from the salivary gland venom of the lizard Heloderma suspectum .

HY-172681

DSPE-PEG2000-VIP	Liposome	Inflammation/Immunology
DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery .

HY-172682

DSPE-PEG5000-VIP	Liposome	Inflammation/Immunology
DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery .

HY-172681A

DSPE-PEG3400-VIP	Liposome	Inflammation/Immunology
DSPE-PEG3400-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG3400-VIP can be used for drug delivery .

HY-RS16586

Vip Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vip Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vip gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vip Mouse Pre-designed siRNA Set A Vip Mouse Pre-designed siRNA Set A

HY-RS15653

VIP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
VIP Human Pre-designed siRNA Set A contains three designed siRNAs for VIP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VIP Human Pre-designed siRNA Set A VIP Human Pre-designed siRNA Set A

HY-RS23021

Vip Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vip Rat Pre-designed siRNA Set A contains three designed siRNAs for Vip gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vip Rat Pre-designed siRNA Set A Vip Rat Pre-designed siRNA Set A

HY-P1015A

VIP(Guinea pig) TFA Vasoactive Intestinal Peptide, guinea pig TFA	PACAP Receptor	Neurological Disease Metabolic Disease
VIP Guinea pig TFA (Vasoactive intestinal peptide), a trophic and mitogenic factor, stimulates growth in whole cultured embryos. VIP Guinea pig functions as a simple gastrointestinal hormone and suggest a possible neurotransmitter function .

HY-P2702

Helodormin	Adenylate Cyclase	Others
Helodormin is a VIP-secretin-like peptide isolated from the venom of the Mexican monster lizard (Heloderma suspectum). Helodormin affects a variety of cellular functions by modulating intracellular signaling through activation of adenylate cyclase. Helodormin can be used to study the evolution and function of the secretin and VIP peptide families .

HY-P0211

[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)	GCGR	Cardiovascular Disease
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human), a growth hormone releasing factor (GRF) analogue, is a vasoactive intestinal peptide (VIP) antagonist .

HY-RS03086

CPAMD8 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CPAMD8 Human Pre-designed siRNA Set A contains three designed siRNAs for CPAMD8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CPAMD8 Human Pre-designed siRNA Set A CPAMD8 Human Pre-designed siRNA Set A

HY-P3053

Helospectin I	GCGR	Cardiovascular Disease
Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

HY-172680

DSPE-PEG1000-VIP	Liposome	Inflammation/Immunology
DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery .

HY-103019R

Enitociclib (Standard) (+)-BAY-1251152 (Standard); (+)-VIP152 (Standard); (S)-Enitociclib (Standard)	Reference Standards Drug Isomer Apoptosis DNA/RNA Synthesis CDK	Cancer
Enitociclib (Standard) is the analytical standard of Enitociclib (HY-103019). This product is intended for research and analytical applications. Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC₅₀=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .

HY-103019AR

(±)-Enitociclib (Standard) (±)-BAY-1251152 (Standard); (±)-VIP152 (Standard)	Reference Standards CDK Apoptosis DNA/RNA Synthesis	Cancer
(±)-Enitociclib (Standard) is the analytical standard of (±)-Enitociclib (HY-103019A). This product is intended for research and analytical applications. (±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-103019BR

(-)-Enitociclib (Standard) (R)-Enitociclib (Standard); (-)-BAY-1251152 (Standard); (-)-VIP152 (Standard)	Reference Standards Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Cancer
(-)-Enitociclib (Standard) is the analytical standard of (-)-Enitociclib (HY-103019B). This product is intended for research and analytical applications. (-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

Cat. No.	Product Name	Type

HY-172681

DSPE-PEG2000-VIP	Biochemical Assay Reagents
DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery .

HY-172682

DSPE-PEG5000-VIP	Biochemical Assay Reagents
DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery .

HY-172681A

DSPE-PEG3400-VIP	Biochemical Assay Reagents
DSPE-PEG3400-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG3400-VIP can be used for drug delivery .

HY-172680

DSPE-PEG1000-VIP	Biochemical Assay Reagents
DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-P0012

Aviptadil 2 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P0221C

PACAP (1-38) free acid	PACAP Receptor	Metabolic Disease
PACAP (1-38) free acid is a desamido-PACAP (1-38), human, ovine, rat (HY-P0221). PACAP (1-38) free acid can activate the human PAC1 receptor. PACAP (1-38) free acid induces cyclic AMP (cAMP) generation in both NS-1 neuroendocrine cells and non-neuroendocrine HEK293 cells .

HY-P0220A

PACAP (6-38), human, ovine, rat TFA 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat TFA is a potent PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P1023

VIP(6-28)(human, rat, porcine, bovine) 1 Publications Verification	GCGR	Metabolic Disease
VIP(6-28)(human, rat, porcine, bovine) is an effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP.

HY-P5005

VIPhyb	CMV PD-1/PD-L1	Infection Inflammation/Immunology Cancer
VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .

HY-P0220

PACAP (6-38), human, ovine, rat 1 Publications Verification	PACAP Receptor	Neurological Disease
PACAP (6-38), human, ovine, rat is a potent PACAP receptor antagonist with IC₅₀s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP₁, and PACAP type II receptor VIP₂, respectively.

HY-P0012A

Aviptadil acetate 2 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting *VIP-VPAC2* signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting *VIP-VPAC2* signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P4195A

*[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate*	IPK Superfamily	Metabolic Disease
[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is the acetate of [K15,R16,L27]VIP(1-7)/GRF(8-27) (HY-P4195). [K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate), a *VIP₁* selective agonist, exhibits IC₅₀ values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP₁, rat VIP₁, rat VIP₂ receptors, respectively . VIP: VASOACTIVE Intestinal Polypeptide

HY-P1159A

*[D-p-Cl-Phe6,Leu17]-VIP* TFA** 1 Publications Verification	PACAP Receptor	Neurological Disease Inflammation/Immunology
[D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of *vasoactive intestinal peptide (VIP) receptor, with the IC₅₀* of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors .

HY-P10948A

*CS-VIP* 8 hydrochloride**	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 hydrochloride is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 hydrochloride induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 hydrochloride is promising for research of hematological diseases such as leukemia .

HY-P4776

*Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP* (1-7)-GRF (8-27)**	PACAP Receptor	Metabolic Disease
Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP (1-7)-GRF (8-27), a vasoactive intestinal peptide (VIP), is a VIP₁ antagonist .

HY-P1159

[D-p-Cl-Phe6,Leu17]-VIP	PACAP Receptor	Neurological Disease Inflammation/Immunology
[D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of *vasoactive intestinal peptide (VIP) receptor, with the IC₅₀* of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors .

HY-P4127A

M65 TFA	PACAP Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
M65 TFA is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P1015

VIP(Guinea pig) Vasoactive Intestinal Peptide, guinea pig	PACAP Receptor	Neurological Disease Metabolic Disease
VIP Guinea pig (Vasoactive intestinal peptide), a trophic and mitogenic factor, stimulates growth in whole cultured embryos. VIP Guinea pig functions as a simple gastrointestinal hormone and suggest a possible neurotransmitter function .

HY-P4127

M65	Peptides	Neurological Disease
M65 is a deleted peptide of maxadilan (61 a.a.) with deletion of the residues between positions 24 and 42 and is a specific antagonist of PACAP type 1 receptor that inhibits ANP secretion and can be used for relevant researches .

HY-P10948

*CS-VIP* 8**	WDR5 Histone Methyltransferase	Cardiovascular Disease
CS-VIP 8 is a selective allosteric WDR5 protein inhibitor (K_i= 0.008 μM). CS-VIP 8 induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 is promising for research of hematological diseases such as leukemia .

HY-P4015

VIP (1-12), human, porcine, rat, ovine	HIV	Neurological Disease Metabolic Disease
VIP (1-12), human, porcine, rat, ovine is a vasoactive intestinal peptide (VIP) fragment. VIP (1-12), human, porcine, rat, ovine is a ligand for the CD4 (T4)/human immunodeficiency virus receptor .

HY-P5111

*Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr free acid*	Peptides	Neurological Disease
Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr (free acid) is a high-affinity and selective VPAC2 receptor antagonist .

HY-P10768A

Ro 25-1553 TFA	PACAP Receptor	Inflammation/Immunology
Ro 25-1553 TFA is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 TFA exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .

HY-P3117

PACAP (6-27) (human, ovine, rat) Pituitary adenylate cyclase-activating peptide (6-27)	Adenylate Cyclase	Neurological Disease
PACAP (6-27) (human, ovine, rat) is a PACAP receptor antagonist that blocks the canine adrenal catecholamine response to exogenous vasoactive intestinal peptide (VIP). PACAP (6-27) (human, ovine, rat) has the potential to study cardiovascular and neurological diseases .

HY-P1767

*Prepro VIP* (81-122), human**	PACAP Receptor	Cardiovascular Disease
Prepro VIP (81-122), human is a prepro-vasoactive intestinal polypeptide (VIP) derived peptide, corresponding to residues 81-122. Peptide histidine valine 42 (PHV-42) has been designated to correspond exactly to Prepro VIP (81-122), which reduces both the force and frequency of spontaneous contractions of isolated rat uterus .

HY-P1158

[Ala2,8,9,11,19,22,24,25,27,28]-VIP	Adenylate Cyclase	Neurological Disease
[Ala2,8,9,11,19,22,24,25,27,28]-VIP is an analog vasoactive intestinal polypeptide (VIP) with high affinity and selectivity for human VIP/pituitary adenylate cyclase-activating polypeptide 1 (hVPAC1). VIP is a widespread neurotransmitter .

HY-P4195

*[K15,R16,L27]VIP(1-7)/GRF(8-27)*	IPK Superfamily	Metabolic Disease
[K15,R16,L27]VIP(1-7)/GRF(8-27), a *VIP₁* selective agonist, exhibits IC₅₀ values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP₁, rat VIP₁, rat VIP₂ receptors, respectively . VIP: VASOACTIVE Intestinal Polypeptide

HY-P10768

Ro 25-1553	PACAP Receptor	Inflammation/Immunology
Ro 25-1553 is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .

HY-P3050

Helospectin II	GCGR	Cardiovascular Disease
Helospectin II is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin II has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin II is originally isolated from the salivary gland venom of the lizard Heloderma suspectum .

HY-P1015A

VIP(Guinea pig) TFA Vasoactive Intestinal Peptide, guinea pig TFA	PACAP Receptor	Neurological Disease Metabolic Disease
VIP Guinea pig TFA (Vasoactive intestinal peptide), a trophic and mitogenic factor, stimulates growth in whole cultured embryos. VIP Guinea pig functions as a simple gastrointestinal hormone and suggest a possible neurotransmitter function .

HY-P2702

Helodormin	Adenylate Cyclase	Others
Helodormin is a VIP-secretin-like peptide isolated from the venom of the Mexican monster lizard (Heloderma suspectum). Helodormin affects a variety of cellular functions by modulating intracellular signaling through activation of adenylate cyclase. Helodormin can be used to study the evolution and function of the secretin and VIP peptide families .

HY-P0211

[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)	GCGR	Cardiovascular Disease
[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human), a growth hormone releasing factor (GRF) analogue, is a vasoactive intestinal peptide (VIP) antagonist .

HY-P4013

*[Arg15,20,21, Leu17] VIP-Gly-Lys-Arg-NH2*	Peptides	Inflammation/Immunology
[Arg15,20,21, Leu17] VIP-Gly-Lys-Arg-NH2 is a vasoactive intestinal polypeptide (VIP) analog with relaxant effects .

HY-P3053

Helospectin I	GCGR	Cardiovascular Disease
Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

HY-P1761

*Prepro VIP* (111-122), human**	Peptides	Neurological Disease
Prepro VIP (111-122), human is a prepro-vasoactive intestinal polypeptide (VIP)-derived peptide, corresponding to residues 111-122. VIP is present in the peripheral and the central nervous systems where it functions as a nonadrenergic, noncholinergic neurotransmitter or neuromodulator .

Species:	Human (5)
Tag:	His (3) GST (1) Fc (1)
Source:	HEK293 (4) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71061

	VIP Protein, Human (HEK293, His) 1 Publications Verification Vasoactive intestinal peptide; VIP; Intestinal peptide PHV-42; Peptide histidine methioninamide 27; Vasoactive intestinal polypeptide	Human	HEK293
	VIP is a neuropeptide that induces vasodilation, lowers arterial blood pressure, stimulates myocardial contractility, enhances glycogenolysis, and relaxes tracheal, gastric, and gallbladder smooth muscles. PHM and PHV-related peptides also have vasodilatory properties. VIP Protein, Human (HEK293, His) is the recombinant human-derived VIP protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71151

	LMAN2 Protein, Human (HEK293, His) Vesicular Integral-Membrane Protein VIP36; Glycoprotein GP36b; Lectin Mannose-Binding 2; Vesicular Integral-Membrane Protein 36; VIP36; LMAN2; C5orf8	Human	HEK293
	LMAN2 Protein, an intracellular lectin, interacts with N-acetyl-D-galactosamine and high-mannose type glycans. This protein is integral to the transport and sorting of glycoproteins with high mannose-type glycans within the early secretory pathway, contributing significantly to cellular processes. LMAN2 Protein, Human (HEK293, His) is the recombinant human-derived LMAN2 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P77099

	NCKIPSD Protein, Human (His) NCK-interacting protein with SH3 domain; VIP54; WISH; AF3P21; SPIN90	Human	E. coli
	NCKIPSD Protein, vital for stress fiber formation induced by active DRF1, stimulates N-WASP-induced ARP2/3 complex activation, independent of CDC42. Implicated in sarcomere maintenance, myofibril assembly, actin polymerization, and angiogenesis. Associates with vimentin, desmin, NCK, GRB2, and interacts with Helicobacter pylori toxin vacA, FHOD1, FASLG, and TMIGD2, showcasing its diverse cellular interactions. NCKIPSD Protein, Human (His) is the recombinant human-derived NCKIPSD protein, expressed by E. coli , with N-His labeled tag.

HY-P70914

	LMAN2L Protein, Human (HEK293, His) VIP36-like protein; Lectin mannose-binding 2-like; LMAN2-like protein; VIPL	Human	HEK293
	The LMAN2L protein plays a critical role in cellular processes and may regulate the export of a specific subset of glycoproteins from the endoplasmic reticulum (ER). Its involvement in glycoprotein export suggests a regulatory function within the endoplasmic reticulum. LMAN2L Protein, Human (HEK293, His) is the recombinant human-derived LMAN2L protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76128

	VIPR2 Protein, Human (HEK293, Fc) Vasoactive intestinal polypeptide receptor 2; VIP-R-2; PACAP-R3; VPAC2; VIPR2	Human	HEK293
	VIPR2 protein, serving as a receptor for Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activating Peptide (PACAP-38 and -27), activates adenylyl cyclase and can also couple with phospholipase C. Its versatile signaling pathways emphasize its pivotal role in transducing signals from VIP and PACAP, participating in cellular processes regulated by cyclic AMP and phosphoinositide signaling cascades. VIPR2 Protein, Human (HEK293, Fc) is the recombinant human-derived VIPR2 protein, expressed by HEK293 , with C-mFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (3) Rat (1) Rabbit (5)
Reactivity:	Human (9) Rat (3) Mouse (3)
Application:	IHC-P (8) IP (1) WB (2) IHC-F (1) FC (1)
Isotype:	IgG (5) IgG1 (3)
Conjugation:	Non-conjugated (9)
Clonality:	Monoclonal (6) Recombinant (4)
Modification:	Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P89010

	AVPI1 Antibody (YA8694) PP5395; VIP32; VIT32	IHC-P	Human
	AVPI1 Antibody (YA8694) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AVPI1.

HY-P81526

	VPAC2 Antibody (YA1271) VIP2R; VIPR2; Vasoactive intestinal polypeptide receptor 2; VIP-R-2; Helodermin-preferring VIP receptor; Pituitary adenylate cyclase-activating polypeptide type III receptor (PACAP type III receptor; PACAP-R-3; PACAP-R3); VPAC2	IHC-P	Human
	VPAC2 Antibody (YA1271) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VPAC2.

HY-P81526A

	VPAC2 Antibody (YA1271)(PBS only) VIP2R; VIPR2; Vasoactive intestinal polypeptide receptor 2; VIP-R-2; Helodermin-preferring VIP receptor; Pituitary adenylate cyclase-activating polypeptide type III receptor (PACAP type III receptor; PACAP-R-3; PACAP-R3); VPAC2	IHC-P	Human
	VPAC2 Antibody (YA1271) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VPAC2.

HY-P89010A

	AVPI1 Antibody (YA8694)(PBS only) PP5395; VIP32; VIT32	IHC-P	Human
	AVPI1 Antibody (YA8694) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to AVPI1.

HY-P83124

	Caveolin 3 Antibody (YA2869) CAV3; M-caveolin; Caveolin 3; VIP21	WB, IP	Human, Mouse, Rat
	Caveolin 3 Antibody (YA2869) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Caveolin 3.

HY-P81524

	VIPR1 Antibody (YA1269) vasoactive inTinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2	IHC-P	Human
	VIPR1 Antibody (YA1269) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VIPR1.

HY-P81524A

	VIPR1 Antibody (YA1269)(PBS only) vasoactive inTinal peptide receptor 1; II; HVR1; RDC1; V1RG; VIPR; VIRG; VAPC1; VPAC1; VPAC1R; VIP-R-1; VPCAP1R; PACAP-R2; PACAP-R-2	IHC-P	Human
	VIPR1 Antibody (YA1269) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VIPR1.

HY-P87318

	MAL Antibody (YA7001) mal antibody; MAL protein gene antibody; Mal T-cell differentiation protein antibody; MAL_HUMAN antibody; MALGENE antibody; MPV17 antibody; Myelin and lymphocyte protein antibody; T-cell differentiation protein MAL antibody; T-lymphocyte maturation-associated protein antibody; VIP17 antibody	WB, IHC-P, FC	Human, Mouse, Rat
	MAL Antibody (YA7001) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MAL.

HY-P87143

	VIP Antibody (YA6836) Peptide histidine methioninamide 27 antibody; Peptide histidine valine 42 antibody; PHM27 antibody; PHV42 antibody; Prepro V; IP : antibody; Vasoactive intestinal peptide antibody; Vasoactive intestinal polypeptide antibody; V; IP : antibody; V; IP : peptides antibody; V; IP : peptides precursor antibody; Peptide histidine methioninamide 27 antibody; Peptide histidine valine 42 antibody; PHM27 antibody; PHV42 antibody; Prepro V; IP : antibody; Vasoactive intestinal peptide antibody; Vasoactive intestinal polypeptide antibody; V; IP : antibody; V; IP : peptides antibody; V; IP : peptides precursor antibody; VIP_HUMAN antibody;	IHC-F, IHC-P	Human, Mouse, Rat
	VIP Antibody (YA6836) is a Rat -derived and non-conjugated monoclonal antibody, targeting to VIP.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: